BDX Related Analyst Ratings
-
Macquarie Upgrades Becton Dickinson (BDX) to Outperform
-
Jefferies Assumes Becton Dickinson (BDX) at Buy
-
Mizuho Securities Downgrades Becton Dickinson (BDX) to Neutral
-
Morgan Stanley Upgrades Becton Dickinson (BDX) to Equalweight
-
BofA/Merrill Lynch Reinstates Becton Dickinson (BDX) at Underperform
-
Stifel Nicolaus Starts Becton Dickinson (BDX) at Hold
-
Barclays Downgrades Becton Dickinson (BDX) to Underweight
-
Barclays Assumes Coverage on Becton Dickinson (BDX) at Equalweight
-
CLSA Downgrades Becton Dickinson (BDX) to Underperform
-
JPMorgan Downgrades Becton Dickinson (BDX) to Underweight
-
Canaccord Genuity Maintains a 'Hold' on Becton Dickinson (BDX); Q3 Preview: Looking For Signs of Stabilization
-
Raymond James Starts MedTech Sector: CFN, COO, COV at Strong Buy, SLTM, ISRG, BAX at Outperform, BDX at Underperform
-
Barclays on U.S. Diagnostics: Q1 Earnings Preview
-
Credit Agricole Downgrades Becton Dickinson (BDX) to Outperform
-
Morgan Stanley Downgrades Becton Dickinson (BDX) to Underweight
-
Canaccord Genuity Maintains a 'Hold' on Becton Dickinson (BDX); Introduces Next-gen Lateral Flow Flu Test
-
Barclays Maintains an 'Equalweight' on Becton Dickinson (BDX); Analyst Day Takeaways
-
Canaccord Genuity Maintains a 'Hold' on Becton Dickinson (BDX); Thoughts Post Analyst Day
-
Barclays on U.S. Diagnostics: Policy, Macro Overhang Persists in Q3
-
Deutsche Bank Cuts Price Target In MedTech
-
Citi Downgrades Becton Dickinson (BDX) to Hold
-
Credit Agricole Starts BDX, COV at Buy, BAX, CFN at Outperform, BCR at Underperform
-
Mizuho Securities Upgrades Becton Dickinson (BDX) to Outperform
-
Goldman Sachs Downgrades Becton Dickinson (BDX) to Neutral
-
CL King Upgrades Becton Dickinson (BDX) to Buy
-
Goldman Sachs Upgrades Becton Dickinson (BDX) to Buy, Sees 17% Upside
-
Jefferies Maintains a 'Buy' on Becton Dickinson (BDX); Early View: Surprisingly Strong 2Q11 Tempered By Core Revenue Outlook Caution
-
Canaccord Genuity on Life Sciences: Biomedical Devices and Services - Japan Crisis: What Is The Impact on Diagnostic Companies?
-
JPMorgan Names 2011's Best, Worst Picks for MedTech Sector (STJ, COV, PODD, BMTI, more)
-
Canaccord Genuity Initiates Coverage on Life Sciences – Biomedical Devices and Services Stocks
-
Canaccord Genuity Starts Becton Dickinson (BDX) at Hold, Price Target $85
-
GARP Research Reiterates a 'Buy' Rating on Cepheid (CPHD); Q2 Results Reinforce Our View
-
Goldman Sachs Starts BCR, CFN at Buy; ISRG, VAR at Sell; BDX Upgraded, ZMH Downgraded
-
Caris Starts Covidien (COV) at Buy, CR Bard (BCR), Becton Dickinson (BDX) at Average
-
Deutsche Bank Initiates Coverage on Becton Dickinson (BDX) with a Hold; Safety in Safety
-
Deutsche Bank Cautiously Starts Coverage on MedTech Stocks, Sees Challenges Ahead; BAX, MDT, COV Named Top Picks
-
Citi Maintains a 'Buy' on Becton, Dickinson (BDX); Model Update & Price Target Revision
-
Leerink Cuts Price Target on Becton, Dickinson (BDX) Shares to $76
-
Macquarie Downgrades Becton, Dickinson and Co. (BDX) to Neutral
-
Goldman Sachs Cuts Numbers On Becton Dickinson (BDX)
-
Highlights On Becton, Dickinson (BDX) From Citi's Healthcare Conference
-
Citi Maintains a 'Hold' on Integra Lifesciences Holdings (IART); Highlights from Meetings with Management at AANS
-
Barclays Initiates Coverage on Becton, Dickinson (BDX) with an Equalweight
-
RBC Starts HOLX, GPRO at Outperform, BEC, CPHD, QGEN at Underperform
-
William Blair Initiates Coverage on Becton, Dickinson & Co. (BDX) with an Outperform
-
CL King Starts Becton, Dickinson and Company (BDX) at Strong Buy, $105 Price Target
-
Piper Jaffray Downgrades Becton, Dickinson (BDX) to Neutral; View Pullbacks into Upper-$60's as Attractive Entry Point
-
Morgan Keegan Makes Ratings Changes to Medical Equipment and Supplies Stocks
-
Citi Starts Beckton Dickinson (BDX) at Buy, $85 Price Target
-
Morgan Keegan Starts BDX, HAE, BCR, MASI, COO at Outperform, BAX, HRC, COV, TFX, ISRG at Market Perform
Back to BDX Stock Lookup
